603 filings
Page 7 of 31
8-K
9a03h18rgg
6 Feb 20
Other Events
6:57am
8-K
eto4h34 87l0
20 Dec 19
Material Modifications to Rights of Security Holders
6:11am
8-K
cav3p
19 Dec 19
Protalix BioTherapeutics Adds Two Accomplished Biopharmaceutical Executives to its Board of Directors
7:03am
CT ORDER
g4v qyvpx
17 Dec 19
Confidential treatment order
3:25pm
8-K
taoa8bnpyjxsm69jkgq
9 Dec 19
Protalix BioTherapeutics Announces 1-for-10 Reverse Stock Split
4:12pm
DEFA14A
qyw7 nru99y
26 Nov 19
Additional proxy soliciting materials
5:00pm
8-K
pqlph
18 Nov 19
No additional clinical trials are necessary for BLA submission, expected by April of 2020
6:57am
DEFA14A
9kx8uiy4mx17i56i5
15 Nov 19
Additional proxy soliciting materials
5:01pm
DEFA14A
tdpml47rr
12 Nov 19
Additional proxy soliciting materials
4:30pm
8-K
o7ite90ojz
7 Nov 19
Protalix BioTherapeutics Reports Third Quarter 2019 Results and Provides Corporate Update
6:56am
8-K
lkd0wto2
17 Oct 19
Other Events
8:43am
8-K
sy2 6eoo7
24 Sep 19
BLA submission anticipated in Q1 2020 through FDA accelerated approval pathway
7:21am
8-K
lx9fdin9w 6mo
30 Aug 19
Protalix BioTherapeutics Receives Listing Deficiency Letter from NYSE American
4:15pm
8-K
j6jx2j58rgz 2h4
13 Aug 19
Shlomo Yanai Resigns as Chairman of the Board of Protalix BioTherapeutics
4:13pm
8-K
vuqhwzhto44f728oi6
8 Aug 19
Protalix BioTherapeutics Reports Second Quarter 2019 Results and Provides Corporate Update
6:19am
8-K
1lc3 5tzcb846jo1
29 Jul 19
Protalix BioTherapeutics Appoints Eyal Rubin as its New Senior Vice President and Chief Financial Officer
7:09am